Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma

Abstract

Colorectal cancer (CRC) and hepatocellular carcinoma (HCC) are the second and third most common causes of death by cancer, respectively. The etiologies of the two cancers are either infectious insult or due to chronic use of alcohol, smoking, diet, obesity and diabetes. Pathological changes in the composition of the gut microbiota that lead to intestinal inflammation are a common factor for both HCC and CRC. However, the gut microbiota of the cancer patient evolves with disease pathogenesis in unique ways that are affected by etiologies and environmental factors. In this review, we examine the changes that occur in the composition of the gut microbiota across the stages of the HCC and CRC. Based on the idea that the gut microbiota are an additional “lifeline” and contribute to the tumor microenvironment, we can observe from previously published literature how the microbiota can cause a shift in the balance from normal → inflammation → diminished inflammation from early to later disease stages. This pattern leads to the hypothesis that tumor survival depends on a less proinflammatory tumor microenvironment. The differences observed in the gut microbiota composition between different disease etiologies as well as between HCC and CRC suggest that the tumor microenvironment is unique for each case.

Key words： gut microbiota; colorectal cancer; hepatocellular carcinoma

References

1 Aly AM, Adel A, El-Gendy AO, Essam TM, Aziz RK (2016) Gut microbiome alterations in patients with stage 4 hepatitis C. Gut Pathog 8:42

2 Arthur JC, Perez-Chanona E, Muhlbauer M, Tomkovich S, Uronis JM, Fan TJ, Campbell BJ, Abujamel T, Dogan B, Rogers AB (2012) Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338:120–123

3 Barrett HL, Gomez-Arango LF, Wilkinson SA, McIntyre HD, Callaway LK, Morrison M, Dekker Nitert M (2018) A vegetarian diet is a major determinant of gut microbiota composition in early pregnancy. Nutrients 10:890

4 Bernstein H, Bernstein C, Payne CM, Dvorakova K, Garewal H (2005) Bile acids as carcinogens in human gastrointestinal cancers. Mutat Res 589:47–65

5 Bernstein C, Holubec H, Bhattacharyya AK, Nguyen H, Payne CM, Zaitlin B, Bernstein H(2011) Carcinogenicity of deoxycholate, a secondary bile acid. Arch Toxicol 85:863–871

6 Bluemel S, Wang L, Kuelbs C,Moncera K, Torralba M, Singh H, Fouts DE, Schnabl B (2019) Intestinal and hepatic microbiota changes associated with chronic ethanol administration in mice. Gut Microbes 14:1–11

7 Boleij A, Hechenbleikner EM, Goodwin AC, Badani R, Stein EM, Lazarev MG, Ellis B, Carroll KC, Albesiano E, Wick EC (2015) The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis 60:208–215

8 Chaucer B, Smith N, Beatty D, Yadav M (2018) Multiple hepatic abscess from parvimonas micra: an emerging gastrointestinal microbe. ACG Case Rep J 5:e70

9 Chen Y, Guo J, Qian G, Fang D, Shi D, Guo L, Li L (2015) Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality. J Gastroenterol Hepatol 30:1429–1437

10 Chen K, Ma J, Jia X, Ai W, Ma Z, Pan Q (2019) Advancing the understanding of NAFLD to hepatocellular carcinoma development: from experimental models to humans. Biochim Biophys Acta Rev Cancer 1871:117–125

11 Chow MD, Lee YH, Guo GL (2017) The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mol Aspects Med 56:34–44

12 Chu H, Duan Y, Yang L, Schnabl B (2019) Small metabolites, possible big changes: a microbiota-centered view of nonalcoholic fatty liver disease. Gut 68:359–370

13 Coppenhagen-Glazer S,Sol A, Abed J,Naor R,Zhang X, Han YW, Bachrach G (2015) Fap2 of Fusobacterium nucleatum is a galactose-inhibitable adhesin involved in coaggregation, cell adhesion, and preterm birth. Infect Immun 83:1104–1113

14 Cosseau C, Devine DA, Dullaghan E, Gardy JL, Chikatamarla A, Gellatly S, Yu LL, Pistolic J, Falsafi R, Tagg J (2008) The commensal Streptococcus salivarius K12 downregulates the innate immune responses of human epithelial cells and promotes host-microbe homeostasis. Infect Immun 76:4163–4175

15 Dai Z, Coker OO, Nakatsu G, Wu WKK, Zhao L, Chen Z, Chan FKL, Kristiansen K, Sung JJY,Wong SH (2018) Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome 6:70

16 De Simone V, Pallone F,Monteleone G,Stolfi C (2013) Role of TH17 cytokines in the control of colorectal cancer. Oncoimmunology 2: e26617

17 De Simone V, Franze E, Ronchetti G, Colantoni A,Fantini MC, Di Fusco D, Sica GS, Sileri P, MacDonald TT, Pallone F (2015) Th17-type cytokines, IL-6 and TNF-alpha synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene 34:3493–3503

18 Dejong CH, van de Poll MC, Soeters PB, Jalan R, Olde Damink SW (2007) Aromatic amino acid metabolism during liver failure. J Nutr 137:1579S–1585S

19 Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB (2019) Colorectal cancer. Lancet 394:1467–1480

20 Despres J, Forano E, Lepercq P, Comtet-Marre S, Jubelin G, Chambon C, Yeoman CJ, Berg Miller ME, Fields CJ, Martens E (2016) Xylan degradation by the human gut Bacteroides xylanisolvens XB1A(T) involves two distinct gene clusters that are linked at the transcriptional level. BMC Genomics 17:326

21 Feng Q, Liang S, Jia H, Stadlmayr A, Tang L,Lan Z, Zhang D, Xia H, Xu X, Jie Z(2015) Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun 6:6528

22 Ferreira DM, Afonso MB, Rodrigues PM, Simao AL, Pereira DM, Borralho PM, Rodrigues CM, Castro RE (2014) c-Jun N-terminal kinase 1/c-Jun activation of the p53/microRNA 34a/sirtuin 1 pathway contributes to apoptosis induced by deoxycholic acid in rat liver . Mol Cell Biol 34:1100–1120

23 Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Nakanishi Y, Uetake C, Kato K, Kato T (2013) Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504:446–450

24 George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G (2003) Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 39:756–764

25 Giloteaux L, Goodrich JK, Walters WA, Levine SM, Ley RE, Hanson MR (2016) Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome . Microbiome 4:30

26 Greathouse KL, Harris CC, Bultman SJ (2015) Dysfunctional families: Clostridium scindens and secondary bile acids inhibit the growth of Clostridium difficile. Cell Metab 21:9–10

27 Guo W, Tan HY, Wang N, Wang X, Feng Y (2018) Deciphering hepatocellular carcinoma through metabolomics: from biomarker discovery to therapy evaluation. Cancer Manag Res 10:715–734

28 Gur C, Ibrahim Y, Isaacson B, Yamin R, Abed J, Gamliel M, Enk J,Bar-On Y, Stanietsky-Kaynan N, Coppenhagen-Glazer S (2015) Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42:344–355

29 Heidrich B, Vital M, Plumeier I, Doscher N, Kahl S, Kirschner J, Ziegert S, Solbach P,Lenzen H, Potthoff A(2018) Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls. Liver Int 38:50–58

30 Hibberd AA, Lyra A, Ouwehand AC, Rolny P, Lindegren H, Cedgard L, Wettergren Y (2017) Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention. BMJ Open Gastroenterol 4:e000145

31 Inoue T, Nakayama J,Moriya K, Kawaratani H, Momoda R, Ito K, Iio E, Nojiri S, Fujiwara K, Yoneda M (2018) Gut dysbiosis associated with hepatitis C virus infection. Clin Infect Dis 67:869–877

32 Kameyama K, Itoh K (2014) Intestinal colonization by a Lachnospiraceae bacterium contributes to the development of diabetes in obese mice. Microbes Environ 29:427–430

33 Kim G, Deepinder F, Morales W, Hwang L, Weitsman S, Chang C, Gunsalus R,Pimentel M(2012) Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. Dig Dis Sci 57:3213–3218

34 Koliaraki V, Pasparakis M, Kollias G (2015) IKKbeta in intestinal mesenchymal cells promotes initiation of colitis-associated cancer . J Exp Med 212:2235–2251

35 Krenkel O, Tacke F (2017) Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol 17:306–321

36 La Reau AJ, Suen G (2018) The Ruminococci: key symbionts of the gut ecosystem. J Microbiol 56:199–208

37 La Rosa SL, Leth ML, Michalak L, Hansen ME, Pudlo NA, Glowacki R, Pereira G,Workman CT , Arntzen MO, Pope PB (2019) The human gut Firmicute Roseburia intestinalis is a primary degrader of dietary beta-mannans. Nat Commun 10:905

38 Leclercq S, Matamoros S, Cani PD, Neyrinck AM, Jamar F, Starkel P, Windey K, Tremaroli V, Backhed F,Verbeke K (2014) Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci USA 111:E4485–4493

39 Li J, Stanger BZ (2019) The tumor as organizer model. Science 363:1038–1039

40 Lin L,Liu A, Peng Z, Lin HJ, Li PK, Li C, Lin J (2011) STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res 71:7226–7237

41 Liu Q, Li F, Zhuang Y, Xu J, Wang J, Mao X, Zhang Y, Liu X (2019) Alteration in gut microbiota associated with hepatitis B and nonhepatitis virus related hepatocellular carcinoma. Gut Pathog 11:1

42 Liu X,Cheng Y, Shao L, Ling Z (2020) Alterations of the predominant fecal microbiota and disruption of the gut mucosal barrier in patients with early-stage colorectal cancer. Biomed Res Int 2020:2948282

43 Long AG, Lundsmith ET, Hamilton KE (2017) Inflammation and colorectal cancer. Curr Colorectal Cancer Rep 13:341–351

44 Loo TM, Kamachi F, Watanabe Y, Yoshimoto S, Kanda H, Arai Y, Nakajima-Takagi Y, Iwama A, Koga T, Sugimoto Y (2017) Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity. Cancer Discov 7:522–538

45 Lopetuso LR, Scaldaferri F, Petito V, Gasbarrini A (2013) Commensal Clostridia: leading players in the maintenance of gut homeostasis. Gut Pathog 5:23

46 Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R (2012) Diversity, stability and resilience of the human gut microbiota. Nature 489:220–230

47 Mizutani S, Yamada T, Yachida S (2020) Significance of the gut microbiome in multistep colorectal carcinogenesis. Cancer Sci 111:766–773

48 Myant KB, Cammareri P, McGhee EJ, Ridgway RA, Huels DJ, Cordero JB, Schwitalla S, Kalna G, Ogg EL, Athineos D (2013) ROS production and NF-kappaB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. Cell Stem Cell 12:761–773

49 Nakatsu G, Li X, Zhou H, Sheng J, Wong SH, Wu WK, Ng SC, Tsoi H, Dong Y,Zhang N (2015) Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun 6:8727

50 O’Callaghan A, van Sinderen D (2016) Bifidobacteria and their role as members of the human gut microbiota. Front Microbiol 7:925

51 Ohtani N, Kawada N (2019) Role of the gut-liver axis in liver inflammation, fibrosis, and cancer: a special focus on the gut microbiota relationship. Hepatol Commun 3:456–470

52 Pan HW, Du LT, Li W, Yang YM, Zhang Y, Wang CX (2020) Biodiversity and richness shifts of mucosa-associated gut microbiota with progression of colorectal cancer. Res Microbiol 1:12. https://doi.org/10.1016/j.resmic.2020.01.001

53 Park CH, Eun CS, Han DS (2018) Intestinal microbiota, chronic inflammation, and colorectal cancer. Intest Res 16:338–345

54 Patel M, Shariff MI, Ladep NG, Thillainayagam AV, Thomas HC, Khan SA, Taylor-Robinson SD (2012) Hepatocellular carcinoma: diagnostics and screening. J Eval Clin Pract 18:335–342

55 Pedersen KB, Pulliam CF, Patel A, Del Piero F,Watanabe TTN, Wankhade UD, Shankar K, Hicks C, Ronis MJ (2019) Liver tumorigenesis is promoted by a high saturated fat diet specifically in male mice and is associated with hepatic expression of the proto-oncogene Agap2 and enrichment of the intestinal microbiome with Coprococcus. Carcinogenesis 40:349–359

56 Petersen C,Round JL (2014) Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol 16:1024–1033

57 Png CW, Linden SK, Gilshenan KS, Zoetendal EG, McSweeney CS, Sly LI, McGuckin MA, Florin TH (2010) Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol 105:2420–2428

58 Porter NT, Luis AS, Martens EC (2018) Bacteroides thetaiotaomicron. Trends Microbiol 26:966–967

59 Rao SG, Jackson JG (2016) SASP: tumor suppressor or promoter? Yes! Trends Cancer 2:676–687

60 Rapozo DC, Bernardazzi C,de Souza HS (2017) Diet and microbiota in inflammatory bowel disease: the gut in disharmony. World J Gastroenterol 23:2124–2140

61 Rey FE, Faith JJ, Bain J, Muehlbauer MJ, Stevens RD, Newgard CB, Gordon JI (2010) Dissecting the in vivo metabolic potential of two human gut acetogens. J Biol Chem 285:22082–22090

62 Ridlon JM, Kang DJ, Hylemon PB (2006) Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47:241–259

63 Rodier F, Campisi J (2011) Four faces of cellular senescence. J Cell Biol 192:547–556

64 Rubinstein MR, Wang X, Liu W, Hao Y,Cai G, Han YW (2013) Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe 14:195–206

65 Saitoh S, Noda S, Aiba Y,Takagi A, Sakamoto M, Benno Y, Koga Y (2002) Bacteroides ovatus as the predominant commensal intestinal microbe causing a systemic antibody response in inflammatory bowel disease. Clin Diagn Lab Immunol 9:54–59

66 Sakamoto M, Takagaki A, Matsumoto K, Kato Y,Goto K , Benno Y (2009) Butyricimonas synergistica gen. nov., sp. nov. and Butyricimonas virosa sp. nov., butyric acid-producing bacteria in the family ‘Porphyromonadaceae’ isolated from rat faeces. Int J Syst Evol Microbiol 59:1748–1753

67 Sandhu BK, McBride SM (2018) Clostridioides difficile. Trends Microbiol 26:1049–1050

68 Schwenger KJP, Chen L, Chelliah A, Da Silva HE, Teterina A, Comelli EM, Taibi A, Arendt BM, Fischer S, Allard JP (2018) Markers of activated inflammatory cells are associated with disease severity and intestinal microbiota in adults with nonalcoholic fatty liver disease. Int J Mol Med 42:2229–2237

69 Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Goktuna SI, Ziegler PK, Canli O, Heijmans J, Huels DJ, Moreaux G (2013) Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152:25–38

70 Soeiro C, Quilici IR, Legoff A, Oussalah MB, Morin M, Alauzet C, Charmillon A (2019 ) Hepatic abscess due to Dialister pneumosintes—a case report. Anaerobe 59:35–37

71 Stenman LK, Holma R, Eggert A, Korpela R (2013) A novel mechanism for gut barrier dysfunction by dietary fat: epithelial disruption by hydrophobic bile acids. Am J Physiol Gastrointest Liver Physiol 304:G227–234

72 Takeshita K, Mizuno S, Mikami Y, Sujino T, Saigusa K, Matsuoka K, Naganuma M, Sato T, Takada T, Tsuji H (2016) A single species of Clostridium Subcluster XIVa decreased in ulcerative colitis patients. Inflamm Bowel Dis 22:2802–2810

73 Thota VR, Dacha S, Natarajan A, Nerad J (2011) Eggerthella lenta bacteremia in a Crohn’s disease patient after ileocecal resection. Fut Microbiol 6:595–597

74 Ullman TA, Itzkowitz SH (2011) Intestinal inflammation and cancer. Gastroenterology 140:1807–1816

75 Upadhyaya B, McCormack L, Fardin-Kia AR, Juenemann R, Nichenametla S, Clapper J, Specker B, Dey M (2016) Impact of dietary resistant starch type 4 on human gut microbiota and immunometabolic functions. Sci Rep 6:28797

76 van den Bogert B, Meijerink M, Zoetendal EG, Wells JM, Kleerebezem M (2014) Immunomodulatory properties of Streptococcus and Veillonella isolates from the human small intestine microbiota . PLoS ONE 9:e114277

77 Voreades N, Kozil A, Weir TL (2014) Diet and the development of the human intestinal microbiome. Front Microbiol 5:494

78 Wang J, Wang Y, Zhang X, Liu J, Zhang Q, Zhao Y, Peng J, Feng Q, Dai J,Sun S et al (2017) Gut microbial dysbiosis is associated with altered hepatic functions and serum metabolites in chronic hepatitis B patients. Front Microbiol 8:2222

79 Wang K, Liao M, Zhou N, Bao L, Ma K, Zheng Z, Wang Y, Liu C, Wang W, Wang J(2019) Parabacteroides distasonis alleviates obesity and metabolic dysfunctions via production of succinate and secondary bile acids. Cell Rep 26(222–235):e225

80 Wexler HM (2007) Bacteroides: the good, the bad, and the nittygritty. Clin Microbiol Rev 20:593–621

81 Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ (2006) Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 40:235–243

82 Wong SH, Zhao L, Zhang X, Nakatsu G, Han J,Xu W, Xiao X, Kwong TNY, Tsoi H, Wu WKK (2017) Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ-free and conventional mice. Gastroenterology 153(1621–1633):e1626

83 Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, Wang Z, Wang C, Zhang Z, Xia W (2014a) gammadeltaT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 40:785–800

84 Wu YJ, Xu MY, Lu LG (2014b) Clinical advances in fibrosis progression of chronic hepatitis B and C. J Clin Transl Hepatol 2:222–227

85 Wu F, Guo X, Zhang J, Zhang M, Ou Z, Peng Y (2017) Phascolarctobacterium faecium abundant colonization in human gastrointestinal tract. Exp Ther Med 14:3122–3126

86 Wu M, Li P, An Y, Ren J, Yan D, Cui J, Li D, Li M, Wang M, Zhong G (2019) Phloretin ameliorates dextran sulfate sodium-induced ulcerative colitis in mice by regulating the gut microbiota. Pharmacol Res 150:104489

87 Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448:427–434

88 Xie G, Wang X, Huang F, Zhao A, Chen W, Yan J, Zhang Y, Lei S, Ge K,Zheng X(2016a) Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. Int J Cancer 139:1764–1775

89 Xie G,Wang X, Liu P, Wei R, Chen W, Rajani C, Hernandez BY, Alegado R, Dong B, Li D (2016b) Distinctly altered gut microbiota in the progression of liver disease. Oncotarget 7:19355–19366

90 Xie YH, Gao QY, Cai GX, Sun XM, Sun XM, Zou TH, Chen HM, Yu SY, Qiu YW, Gu WQ (2017) Fecal Clostridium symbiosum for noninvasive detection of early and advanced colorectal cancer: test and validation studies. EBioMedicine 25:32–40

91 Yachida S, Mizutani S, Shiroma H, Shiba S, Nakajima T, Sakamoto T, Watanabe H, Masuda K, Nishimoto Y,Kubo M (2019) Metagenomic and metabolomic analyses reveal distinct stagespecific phenotypes of the gut microbiota in colorectal cancer. Nat Med 25:968–976

92 Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, Qian Y, Kryczek I, Sun D, Nagarsheth N (2017) Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 170(548–563):e516

93 Zeng Y, Chen S, Fu Y,Wu W, Chen T, Chen J, Yang B, Ou Q (2020) Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. J Viral Hepat 27:143–155

94 Zhang Z, Zhai H, Geng J, Yu R, Ren H, Fan H, Shi P (2013) Largescale survey of gut microbiota associated with MHE Via 16S rRNA-based pyrosequencing. Am J Gastroenterol 108:1601–1611

95 Zhang Y, Yu X, Yu E, Wang N, Cai Q, Shuai Q, Yan F,Jiang L, Wang H, Liu J (2018) Changes in gut microbiota and plasma inflammatory factors across the stages of colorectal tumorigenesis: a case-control study. BMC Microbiol 18:92